Janus Henderson Group PLC Has $70.92 Million Stake in Zai Lab Limited (NASDAQ:ZLAB)

Janus Henderson Group PLC increased its position in Zai Lab Limited (NASDAQ:ZLAB) by 9.6% during the first quarter, HoldingsChannel reports. The institutional investor owned 4,428,011 shares of the company’s stock after acquiring an additional 387,729 shares during the period. Janus Henderson Group PLC’s holdings in Zai Lab were worth $70,924,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZLAB. Bamco Inc. NY increased its stake in shares of Zai Lab by 7.3% during the 1st quarter. Bamco Inc. NY now owns 1,599,865 shares of the company’s stock worth $25,630,000 after purchasing an additional 108,991 shares during the last quarter. Capital World Investors boosted its holdings in Zai Lab by 8.9% in the first quarter. Capital World Investors now owns 5,684,180 shares of the company’s stock worth $91,061,000 after purchasing an additional 465,337 shares in the last quarter. Capital International Inc. CA increased its position in Zai Lab by 6.7% during the first quarter. Capital International Inc. CA now owns 92,108 shares of the company’s stock worth $1,476,000 after buying an additional 5,815 shares during the last quarter. M&G Plc bought a new position in Zai Lab during the first quarter valued at about $7,266,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Zai Lab by 51.1% during the 1st quarter. Russell Investments Group Ltd. now owns 293,783 shares of the company’s stock worth $4,706,000 after acquiring an additional 99,355 shares in the last quarter. Institutional investors own 41.65% of the company’s stock.

Zai Lab Trading Down 2.2 %

NASDAQ:ZLAB traded down $0.42 during mid-day trading on Tuesday, hitting $18.37. 464,836 shares of the company’s stock traded hands, compared to its average volume of 621,506. The firm has a 50 day moving average of $18.50 and a two-hundred day moving average of $18.74. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -5.38 and a beta of 1.06. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $31.66.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.38. Zai Lab had a negative net margin of 116.45% and a negative return on equity of 40.21%. The business had revenue of $87.15 million for the quarter, compared to the consensus estimate of $77.07 million. During the same quarter last year, the company posted ($0.51) earnings per share. As a group, equities research analysts expect that Zai Lab Limited will post -2.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. reduced their target price on Zai Lab from $43.00 to $38.00 and set an “overweight” rating for the company in a report on Friday, July 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research note on Monday, July 1st. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $58.97.

Insiders Place Their Bets

In other Zai Lab news, CEO Ying Du sold 23,939 shares of the company’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $17.90, for a total value of $428,508.10. Following the completion of the transaction, the chief executive officer now owns 1,142,833 shares of the company’s stock, valued at approximately $20,456,710.70. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Frazor Titus Edmondson III sold 10,000 shares of Zai Lab stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $21.33, for a total transaction of $213,300.00. Following the sale, the insider now directly owns 16,408 shares in the company, valued at approximately $349,982.64. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Ying Du sold 23,939 shares of the stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $17.90, for a total transaction of $428,508.10. Following the completion of the transaction, the chief executive officer now directly owns 1,142,833 shares of the company’s stock, valued at approximately $20,456,710.70. The disclosure for this sale can be found here. Insiders have sold 60,934 shares of company stock worth $1,116,043 in the last ninety days. Insiders own 5.23% of the company’s stock.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.